Immunotherapy & Vaccines

JPT Peptide Technologies possesses a variety of unique peptide based technologies allowing for systematic and proteome spanning B- and T-cell biomarker discovery, immune monitoring and clinical development of immunotherapy and vaccines. Our tools and know-how are currently and have been successfully used in various projects leading to novel approaches in indications such as cancer, infection, autoimmune disease and allergy.

In contrast to other approaches on the market, our technologies enable the monitoring of individual epitope patterns as well as epitope spreading and address natural sequence diversity and post-translational modifications.

Contact us for further information and discussion!

Applications

Epitope discovery: JPT offers its technologies and expertise in discovery projects targeting specific B- and T-cell epitopes that can be used as markers for early diagnosis and progression of diseases as well as patient stratification. For the first time, high-throughput proteome spanning screening can be combined with high resolution epitope based profiling.
Development of immune monitoring tools: JPT applies its patented approaches and know-how to develop peptide based immune monitoring tools targeting specific antigens or antigen families. The combination of technological and bioinformatic know-how with profound expertise in assay development provides efficient access to epitope resolved profiling for cellular and humoral immune responses.
Assay development & sample profiling: JPT’s experienced scientists will work with you to develop the optimal screening strategy for your project. Seroprofiling assays and T cell assays are performed in JPT’s S2 laboratories using automatic incubation stations and trained staff assuring performance of robust and reproducible results.

Benefits

Broad peptide technology portfolio for all development phases of immunotherapies and vaccines
Peptide platforms covering cellular and humoral immunity
Ultra-high content peptide library concepts for deep epitope and target discovery
Clinical peptides
Chemical synthesis addresses sequence diversity and post-translational modifications
State of the art infrastructure allowing organic chemistry, sensitive production workflows (cleanroom) and assays including usage of infectious patient materials (S2 and gene tech laboratories)
Comprehensive bioinformatics for peptide selection and design

References

A Vaccine Based on Recombinant Modified Vaccinia Ankara Containing the Nucleoprotein from Lassa Virus Protects Against Disease Progression in a Guinea Pig Model
Kennedy et al, Vaccine (2019)
Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients
Baraniak et al, Journal of Infectious Disease (2019)
Mass Spectrometry Driven Exploration Reveals Nuances of Neoepitope-Driven Tumor Rejection
Ebrahimi-Nik et al, JCI Insight (2019)
New Epitopes in Ovalbuminprovide Insights For Cancer Neoepitopes
Karandikar et al, Immunology (2019)
Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy
Murphy et al, Journal of Proteome Research (2019)
Natural T Cell Autoreactivity to Melanoma Antigens: Clonally Expanded Melanoma-Antigen Specific CD8 + Memory T Cells Can be Detected in Healthy Humans
Przybyla et al, Cancer Immunology, Immunotherapy (2019)
Characterization of the Immune Response Elicited by the Vaccinia Virus L3 Protein Delivered as Naked DNA
Ramírez et al, Vaccine (2018)
Epstein-Barr Virus (EBV)-derived BARF1 Encodes CD4-and CD8-restricted Epitopes as Targets for T-cell Immunotherapy
Kalra et al, Cytotherapy (2018)
PRAME Peptide‐Specific CD8+ T Cells Represent the Predominant Response Against Leukemia‐Associated Antigens (LAAs) in Healthy Individuals
Matko et al, European Journal of Immunology (2018)
Coordinated Responses to Individual Tumor Antigens by IgG Antibody and CD8+ T cells Following Cancer Vaccination
Hulett et al, Journal for ImmunoTherapy of Cancer (2018)